200
Participants
Start Date
September 30, 2014
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
GC6101A 37.5mg
Administer 12.5mg of GC6101A t.i.d for 2 weeks.
GC6101A 75mg
Administer 25mg of GC6101A t.i.d for 2 weeks.
GC6101A 150mg
Administer 50mg of GC6101A t.i.d for 2 weeks.
Placebo
Administer placebo t.i.d for 2 weeks
RECRUITING
Inje University, Busan Paik Hospital of Korea, Busan
RECRUITING
Keimyung University, Dongsan Medical Center of Korea, Daegu
RECRUITING
Wonkwang University, Hospital of Korea, Iksan-si
RECRUITING
Seoul National University, Bundang Hospital of Korea, Seongnam-si
RECRUITING
Chungang University, Hospital of Korea, Seoul
RECRUITING
Ewha Womans University, Medical Center of Korea, Seoul
RECRUITING
Inje University, Seoul Paik Hospital of Korea, Seoul
RECRUITING
Kankbuk Samsung Medical Center of Korea, Seoul
RECRUITING
Korea University, Guro Hospital of Korea, Seoul
RECRUITING
Seoul National University, Hospital of Korea, Seoul
NOT_YET_RECRUITING
Soonchunhyang University, Seoul Hospital of Korea, Seoul
RECRUITING
The Catholic University, Seoul St. Mary's Hospital of Korea, Seoul
RECRUITING
Yonsei University, Gangnam Severance Hospital of Korea, Seoul
RECRUITING
Ajou University, Medical Center of Korea, Suwon
Lead Sponsor
Collaborators (2)
C&R Research, Inc.
INDUSTRY
CRScube
UNKNOWN
Green Cross Corporation
INDUSTRY